Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epratuzumab + rituximab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Epratuzumab + rituximab** is a combination of two monoclonal antibodies targeting distinct B-cell antigens, CD22 and CD20, respectively. Epratuzumab is a humanized anti-CD22 antibody (hLL2, LymphoCide), acting as an immunomodulator by modulating B-cell activity without causing extensive B-cell depletion. Rituximab is a chimeric anti-CD20 antibody (Rituxan) that induces cytotoxic effects on B cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and apoptosis, leading to lysis of CD20-expressing B lymphocytes. The combination has been explored in clinical trials for relapsed/refractory non-Hodgkin’s lymphoma (NHL), including follicular lymphoma and diffuse large B-cell lymphoma, where it has shown a favorable safety profile and promising clinical activity[1][3][4][5][7]. The rationale is complementary mechanisms: epratuzumab’s immunomodulation with rituximab’s cytotoxicity may enhance antitumor efficacy while maintaining tolerability[2][4].
- Other names
- epratuzumab + rituximabanti-CD22 + anti-CD20 monoclonal antibody combination
02
Targets
CD22 (Cluster of Differentiation 22)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on epratuzumab + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epratuzumab + rituximab.